首页> 外文OA文献 >Spray coating of microcontainers with eudragit using ferromagnetic shadow masks for controlled oral release of poorly water soluble drugs.
【2h】

Spray coating of microcontainers with eudragit using ferromagnetic shadow masks for controlled oral release of poorly water soluble drugs.

机译:使用铁磁阴影掩模用eudragit喷涂微容器,用于控制口服释放水溶性差的药物。

摘要

PURPOSE: To form a lid of Eudragit S-100 or L-100 on the cavity of drug-filled microcontainers (micro scale oral drug delivery devices) by utilizing ferromagnetic masks. Furthermore, investigations of drug release in biorelevant gastric and intestinal media were evaluated for testing the ability of controlling the drug release of poorly soluble drugs from the microcontainers.METHODS: Cylindrical microcontainers (inner diameter of 240 μm) were fabricated in SU-8, using photolithography on silicon substrate. The microcontainers were filled with either cinnarizine (weak base) or amorphous furosemide salt (weak acid). The cavity of the drug-filled microcontainers were spray coated with a 2 wt% solution of either Eudragit S-100 (soluble below pH 5) or Eudragit L-100 (soluble above pH 6) in isopropanol. The spray coating process was performed using ferromagnetic shadow masks (380 μm) allowing for magnetic clamping to the substrate and therefore precise deposition of the polymer on the microcontainers to form a lid. The release of cinnarizine and amorphous furosemide salt from the coated microcontainers was performed in fasted biorelevant gastric (pH 1.6) and intestinal media (pH 6.5), respectively.RESULTS: By use of the ferromagnetic shadow masks it was possible to deposit the Eudragit precisely and therefore possible to form a lid of the cavity of the microcontainers. The thickness of the Eudragit layer on the cavity of the microcontainers was approximately 8-10 μm for both types of Eudragit. It was possible to control the drug release of cinnarizine by using Eudragit L-100 in the gastric medium and also possible to control the release of amorphous furosemide salt by the Eudragit E-100 coating in the intestinal medium.CONCLUSIONS: The ferromagnetic shadow masks made it possible to deposit a lid of Eudragit on the cavity of the microcontainers and this is important in terms of utilizing the microcontainers as an oral drug delivery system as the drug release can be controlled.
机译:目的:通过使用铁磁面罩,在装有药物的微型容器(微型口服药物输送装置)的空腔上形成Eudragit S-100或L-100的盖子。此外,评估了在生物相关的胃和肠介质中药物释放的研究,以测试控制微容器中难溶性药物释放的能力。方法:在SU-8中制造圆柱形微容器(内径为240μm),使用在硅衬底上的光刻。微容器中填充了肉桂利嗪(弱碱)或无定形速尿盐(弱酸)。用2重量%的Eudragit S-100(在pH 5以下可溶)或Eudragit L-100(在pH 6以上可溶)的异丙醇溶液喷涂药物填充的微容器的腔。喷涂过程使用铁磁性荫罩(380μm)进行,可将磁性夹持到基材上,从而将聚合物精确沉积在微容器上以形成盖子。禁食的生物相关胃(pH 1.6)和肠介质(pH 6.5)分别从包被的微容器中释放肉桂利嗪和无定形呋塞米盐。结果:通过使用铁磁荫罩,可以精确地沉积Eudragit和因此,可以形成微容器腔的盖。对于两种类型的Eudragit,微容器腔上的Eudragit层的厚度约为8-10μm。结论:用Eudragit E-100涂层在肠介质中可以控制Eudragit L-100在胃介质中的释放,并可以控制无定形速尿盐的释放。有可能在微容器的腔体上沉积一个Eudragit的盖子,这在利用微容器作为口服药物输送系统方面很重要,因为可以控制药物的释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号